Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment

Rueil-malmaison,,France,-,August,13,,2023:,Exterior,View,Of,The

The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE) and Shionogi Inc.

NICE has recommended ViiV Healthcare’s Apretude (cabotegravir) as a pre-exposure prophylaxis (PrEP) for individuals at high risk of HIV-1, marking it as the first injectable PrEP and the first to be appraised by NICE.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.